Results 311 to 320 of about 39,319 (333)
Some of the next articles are maybe not open access.
New Approved Indication for Ibrutinib
AJN, American Journal of Nursing, 2014* Ibrutinib (Imbruvica) has been approved to treat chronic lymphocytic leukemia in patients who've received treatment at least once with other drug therapy. * Common adverse effects are numerous and include thrombocytopenia, diarrhea, bruising, neutropenia, anemia, upper respiratory tract infection, fatigue, musculoskeletal pain, rash, fever ...
openaire +3 more sources
Ibrutinib in B lymphoid malignancies
Expert Opinion on Pharmacotherapy, 2015Most lymphomas and lymphoid leukemias are of B cell origin. Indolent B cell lymphomas, most commonly follicular lymphoma but including Waldenstrom's macroglobulinemia and mantle cell lymphoma, as well as chronic lymphocytic leukemia, are incurable with standard therapy. New treatments are needed.
openaire +3 more sources
Overcoming ibrutinib resistance
Science-Business eXchange, 2014The CDK4 inhibitor palbociclib might help overcome ibrutinib resistance in mantle cell lymphoma by restoring sensitivity to inhibitors of BTK or PI3K.
openaire +2 more sources
Ibrutinib for Chronic Lymphocytic Leukemia
New England Journal of Medicine, 2016Antonio Cuneo +2 more
openaire +6 more sources
Fluconazole Increases Ibrutinib Concentration
American Journal of Therapeutics, 2020Toyotaka Kawamata +3 more
openaire +3 more sources
Ventricular Tachycardia Caused by Ibrutinib
The Journal of Emergency Medicine, 2017János Tomcsányi +2 more
openaire +3 more sources
Ibrutinib: searching for a partner drug
The Lancet Oncology, 2019Arnon P. Kater, Jennifer R. Brown
openaire +3 more sources